Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Propanc Biopharma Inc (PPCB)

Propanc Biopharma Inc (PPCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,749
  • Shares Outstanding, K 12,807
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,920 K
  • EBIT $ -62 M
  • EBITDA $ -62 M
  • 60-Month Beta 3.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -45.12
  • Most Recent Earnings $-0.39 on 11/14/25
  • Next Earnings Date 11/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7300 +14.97%
on 11/14/25
1.2600 -33.39%
on 12/01/25
-0.3407 (-28.87%)
since 11/05/25
3-Month
0.7300 +14.97%
on 11/14/25
2.5000 -66.43%
on 09/12/25
-1.3107 (-60.96%)
since 09/05/25
52-Week
0.7300 +14.97%
on 11/14/25
145.4600 -99.42%
on 01/29/25
-17.1607 (-95.34%)
since 12/05/24

Most Recent Stories

More News
$100 Million Deal Positions This Microcap at the Crossroads of Biotech and Digital Finance

The worlds of biotechnology and cryptocurrency are colliding in unprecedented ways. Once viewed as niche markets, digital assets are increasingly finding a role in corporate treasuries, offering liquidity,...

TSLA : 455.00 (+0.10%)
PPCB : 0.8393 (+1.73%)
MRNA : 27.70 (+8.67%)
COIN : 269.73 (-1.58%)
Propanc Biopharma Enters Securities Purchase Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

PPCB : 0.8393 (+1.73%)
From Lab Bench to Blockchain: How Biotech is Reinventing Funding

The %Biotech field is no stranger to scientific breakthroughs, but combining novel therapeutic platforms with progressive treasury strategies is relatively new, and potentially disruptive. Many companies,...

ETHZ : 10.51 (-10.86%)
^ETHUSD : 3,038.980 (+0.60%)
QNTM : 10.04 (+0.40%)
QNTM.CN : 14.1200 (+2.39%)
PPCB : 0.8393 (+1.73%)
^ETHUSDT : 3,041.794 (+0.74%)
BTCS : 3.33 (-2.63%)
^ETHBTC : 0.033847 (-0.04%)
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads

Innovation in %Biotech often comes from pushing both science and finance into new territory. As drug developers race toward clinical trials, two levers often distinguish those that succeed: strong intellectual...

MSTR : 178.99 (-3.77%)
BMNR : 34.06 (-6.22%)
^BTCUSDT : 89,875.23 (+0.77%)
PPCB : 0.8393 (+1.73%)
HOTH : 1.2000 (+0.84%)
^BTCUSD : 89,814.20 (+0.69%)
Stopping Cancer Before It Spreads: The EMT Revolution in Oncology

Cancer's most insidious ability lies not just in its capacity to grow, but in its power to transform. When tumor cells undergo epithelial-to-mesenchymal transition (EMT), they shed their structured, anchored...

PPCB : 0.8393 (+1.73%)
RHHBY : 48.5200 (+0.66%)
PFE : 26.03 (+1.28%)
BMY : 52.15 (+0.38%)
Biotechs Big Bang: IPOs, Uplists and the Short Squeeze Effect

When a microcap %Biotech transitions from obscurity to the Nasdaq Capital Market, fireworks are common. The move often signals a pivotal moment in the company's growth trajectory, opening the door to broader...

SANA : 5.13 (-0.97%)
RHHVF : 383.4620 (-2.97%)
$SANA : 3,452.65 (+8.59%)
PPCB : 0.8393 (+1.73%)
MRNA : 27.70 (+8.67%)
The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms

- Bristol Myers Squibb, Merck & Company, and GE Healthcare Technologies continue advancing the cancer care ecosystem through cutting-edge therapeutics and diagnostic innovations

NVDA : 182.41 (-0.53%)
MRK : 99.72 (-1.16%)
GEHC : 85.46 (+3.56%)
PPCB : 0.8393 (+1.73%)
BMY : 52.15 (+0.38%)
BNTX : 96.25 (+0.26%)
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer,...

OTC.VN : 0.740 (unch)
PPCB : 0.8393 (+1.73%)
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer,...

OTC.VN : 0.740 (unch)
PPCB : 0.8393 (+1.73%)
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer,...

OTC.VN : 0.740 (unch)
PPCB : 0.8393 (+1.73%)

Business Summary

Propanc Biopharma, Inc. is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company's products include PRP and PRP-DCM. Propanc Biopharma, Inc., formerly known as Propanc Health Group Corporation, is based...

See More

Key Turning Points

3rd Resistance Point 0.9339
2nd Resistance Point 0.8911
1st Resistance Point 0.8652
Last Price 0.8393
1st Support Level 0.7965
2nd Support Level 0.7537
3rd Support Level 0.7278

See More

52-Week High 145.4600
Fibonacci 61.8% 90.1731
Fibonacci 50% 73.0950
Fibonacci 38.2% 56.0169
Last Price 0.8393
52-Week Low 0.7300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar